Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial-Reference-Cited by-同舟云学术

Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial

Published:2017-04-27 Issue:2 Volume:46 Page:142-149
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Roblin X.¹^ORCID,Boschetti G.²,Williet N.¹,Nancey S.²,Marotte H.³,Berger A.⁴,Phelip J. M.¹,Peyrin-Biroulet L.⁵,Colombel J. F.⁶^ORCID,Del Tedesco E.¹,Paul S.⁴,Flourie B.²

Affiliation:

1. Department of Gastroenterology; University Hospital of Saint Etienne; Saint Etienne France

2. Department of Gastroenterology; Hospices Civils de Lyon; INSERM U1111; Lyon France

3. Department of Rheumatology; University Hospital of Saint Etienne; Saint Etienne France

4. Department of Immunology; CIC1408; GIMAP EA3064; University Hospital of Saint Etienne; Saint Etienne France

5. Department of Gastroenterology; University Hospital of Nancy; Nancy France

6. Division of Gastroenterology; Inflammatory Bowel Disease Center; Icahn School of Medicine; Mount Sinai Hospital; New York NY USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14106/fullpdf

Reference32 articles.

1. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

2. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis;Panaccione;Gastroenterology,2014

3. Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab;Osterman;Am J Gastroenterol,2016

4. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn's disease;Osterman;Clin Gastroenterol Hepatol,2015

5. Risk factors for opportunistic infections in patients with inflammatory bowel disease;Toruner;Gastroenterology,2008

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases;Journal of Clinical Medicine;2024-08-09

3. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

4. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study;The Lancet Gastroenterology & Hepatology;2024-06

5. PANTS extension study: how best to use anti-TNF drugs in Crohn's disease;The Lancet Gastroenterology & Hepatology;2024-06